# Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

> **NCT02566057** · NA · COMPLETED · sponsor: **Northwell Health** · enrollment: 36 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder
- Psychotic Disorders
- Bipolar Disorder

## Interventions

- **BIOLOGICAL:** PGx testing guided treatment (PGT)

## Key facts

- **NCT ID:** NCT02566057
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-10
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566057, "Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02566057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*